Akeso, Inc. is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, has received marketing approval from ...
CSL Behring K.K. President and Representative Director: Izumi Yoshida) announced that it launched ANDEMBRY® Subcutaneous Injection 200 mg P...
Endevica Bio, a privately held company developing first-in-class peptide drug candidates, announced the dose administration for the first patient in a Phas...
Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), announced its investment in Feldan Therapeutics...
JelloX Biotech Inc., a Taiwan-based startup at the forefront of cancer pathology, announced the preliminary results of a research collaboration ...
Eisai Co., Ltd. and Biogen Inc. announced that the European Commission (EC) has granted marketing authorization (MA) for Leqembi® (lecanemab), a m...
Nikon CeLL innovation Co., Ltd. (NCLi), a subsidiary of Nikon Corporation has entered into a strategic licensing agreement with RoosterBio, Inc. (RoosterBi...
Partnership with specialist life science distributor establishes sales channel in high-demand market and strengthens global network Hypothermic pres...
Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug Conjug...
Certara, Inc. a global leader in model-informed drug development, announced the launch of its Non-Animal Navigator™ solution designed to help bi...
Celltrion, Inc. announced that the U.S. Food and Drug Administration (FDA) has designated YUFLYMA® (adalimumab-aaty), as an interchangeable biosim...
Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need. The ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that results from a Phase 3 registrational clinical study evaluating...
Amgen, announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with ...
© 2025 Biopharma Boardroom. All Rights Reserved.
